A case of Lenvatinib-induced Focal Segmental Glomerulosclerosis (FSGS) in metastatic medullary thyroid cancer

Fleming, K., McGuinness, J., Kipgen, D., Glen, H. and Spiliopoulou, P. (2018) A case of Lenvatinib-induced Focal Segmental Glomerulosclerosis (FSGS) in metastatic medullary thyroid cancer. Case Reports in Oncological Medicine, 2018, 6927639. (doi: 10.1155/2018/6927639) (PMID:30402314) (PMCID:PMC6192131)

Abstract

We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encountered during the treatment of metastatic medullary thyroid cancer. Proteinuria is a relatively common side effect of VEGF-targeted treatments and can occasionally result in treatment discontinuation. Here, we describe a patient who developed secondary FSGS necessitating discontinuation of treatment at first but who was subsequently rechallenged with anti-VEGF-targeted treatment without recurrence of proteinuria. Lenvatinib was a novel experimental agent at the time the treatment took place; however, its recent licensing for the treatment of thyroid malignancies in the UK makes reporting of these adverse effects all the more important now.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Spiliopoulou, Dr Pavlina
• Authors: Fleming, K., McGuinness, J., Kipgen, D., Glen, H., and Spiliopoulou, P.
• College/School: College of Medical Veterinary and Life Sciences > School of Cancer Sciences
• Journal Name: Case Reports in Oncological Medicine
• Publisher: Hindawi
• ISSN: 2090-6706
• ISSN (Online): 2090-6714
• Copyright Holders: Copyright © 2018 Kathryn Fleming et al.
• First Published: First published in Case Reports in Oncological Medicine 2018:6927639
• Publisher Policy: Reproduced under a Creative Commons licence